BRAF mutations have been identified in approximately 5% of all malignancies, with the highest incidence observed in melanoma (39.7%), thyroid cancer (33.3%), small intestinal malignancies (8.9%), and non‐small cell lung cancer (NSCLC) (2%–5%) [1]. This evidence concerns the gene BRAF and thyroid gland carcinoma.